Fresh analysis suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt conventional lifestyle regimens.
Research printed in a major health publication points out that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month once they quit.
"Users using such treatments must be cognizant of the danger of rapid rebound weight gain when the medication concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to starting weight in about a year and a half.
Analyzing Treatments
The analysis, which looked at 37 of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with conventional dieting.
Scientists emphasize that individuals who lose weight through lifestyle changes alone usually experience a slower weight regain—approximately 100 grams monthly—after stopping.
Understanding the Rapid Regain
Doctors suggest the mechanism of the jabs explains the accelerated rebound.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of the hormone levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement means appetite is uncontrolled, making binge eating far more likely."
A Lifelong Condition?
The NHS suggest the jabs for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, considering the significant potential of relapse, the therapy should be considered life-long.
This opinion is supported by pharmaceutical companies, who state that the findings "highlight the persistent character of obesity," similar to managing diseases like diabetes.
Patient Experiences
People who have stopped the jabs explain a intense return of cravings.
"It felt as if a trigger that goes on and you're instantly extremely hungry," recalled one woman.
The struggle is compounded if users have not established sustainable lifestyle or habit changes during therapy.
Significant Use
Figures indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers caution that while the jabs are powerful agents for weight loss, they are not a permanent fix and long-term success relies on ongoing behavioural support.
